Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C114383
http://purl.obolibrary.org/obo/NCIT_C114383
|
|---|---|
| Preferred Name | Ivosidenib |
| Definitions |
An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. |
|---|---|
| prefLabel | Ivosidenib
|
| label | Ivosidenib
|
| NCI_META_CUI | CL471818
|
| PDQ_Closed_Trial_Search_ID | 758551
|
| code | C114383
|
| Has_Target | |
| prefixIRI | NCIT:C114383
|
| in_subset |
See more
See less
|
| Display_Name | Ivosidenib
|
| Preferred_Name | Ivosidenib
|
| FDA_UNII_Code | Q2PCN8MAM6
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Ivosidenib
|
| CAS_Registry | 1448347-49-6
|
| NCI_Drug_Dictionary_ID | 758551
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 758551
|
| Accepted_Therapeutic_Use_For | newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |